

Special Issue

Advanced Research in Surgical Treatment for Spinal Tumors

Message from the Guest Editors

Tumors affecting the spine represent a challenging pathologic entity that requires collaboration among practitioners with multiple medical specialties. The life expectancy of patients affected by tumors of the spine (primary or metastatic) has increased considerably, mainly due to advances in the field of oncologic therapies, radiotherapy, and surgical treatments.

Molecular targeted therapy is changing the way in which we treat cancer. Knowing the molecular signature of a specific tumor can lead to the development of targeted therapy and improve outcomes.

In parallel, the use of spinal surgery has considerably increased worldwide over the last 30 years, leading to the development of new and often minimally invasive surgical approaches and techniques.

For this Special Issue, we invite articles on surgical treatment for spinal tumors (such as interventional radiology, radiosurgery, robotic-assisted surgery, and electrochemotherapy), focusing on outcomes in terms of survival, complications, recurrence, and quality of life. Both original articles and reviews are welcome, and interesting "Communication" will also be considered.

Guest Editors

Prof. Dr. Alessandro Gasbarrini

Dr. Stefano Bandiera

Dr. Giuseppe Tedesco

Deadline for manuscript submissions

31 December 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/233080

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)